Partnerships

Danner Laboratory was founded in San Diego, California, in 1991. Over two decades later, Danner Laboratory was acquired by General Biologicals Company (GBC) in Taiwan. Along with this, Danner has been able to expand its North American operations into Vancouver, Canada. Currently, we are focusing on generating many fruitful partnerships by sharing the the innovative technologies that have been developed within our laboratory.

Partnering with insurance companies allows CTCReveal™ to reduce mortality in high-risk populations, improving policyholder longevity, while enhancing insurers’ financial performance through delayed claims and stronger return on investment.

• Reduces cancer mortality in high-risk cohorts
• Improves policyholder retention and lifespan
• Delays death claims to older ages
• Cuts long-term payout costs
• Increases perceived premium value
• Estimated ROI improvement exceeding 30%
• Positions insurers as proactive, prevention-focused providers
• Potential for value-based care reimbursement models
• Enhances insurers’ ESG (environmental, social, governance) health impact metrics

Collaborating with pharmaceutical research organizations allows CTCReveal™ data and samples to accelerate drug development, improve FDA approval success rates, and expand research capabilities through increased patient sample volume.

• Contributes real-world CTC data to drug development pipelines
• Enhances early-stage therapeutic target identification
• Improved probability of FDA approval success
• Provides access to larger patient sample pools
• Enables higher-volume research at Danner Laboratory
• Supports biomarker validation studies
• Facilitates clinical trial recruitment
• Opens opportunities for co-developed diagnostics and companion diagnostics
• Potential for licensing agreements and shared intellectual property

CTCReveal™ enables earlier cancer risk detection than traditional imaging, empowering oncologists and corporate health programs to intervene proactively and monitor patients before late-stage metastasis occurs.

• Detects CTCs before imaging shows tumors
• Triggers follow-up with PET-CT, CT, or MRI scans when necessary
• Supports proactive monitoring before late-stage metastasis
• Enhances preventive oncology models
• Improves patient outcomes through earlier intervention
• Reduces late-stage treatment costs
• Strengthens oncologists’ diagnostic precision and patient management strategies

Partnerships with CLIA-certified laboratories and clinics expand patient access to CTCReveal™ while generating high-quality clinical data, supporting diagnostic validation, and creating joint research and funding opportunities.

• Expands patient acquisition and steady sample flow
• Provides biopsy, blood, and tissue samples
• Improves diagnostic validation and accuracy
• Generates real-world clinical performance data
• Enables joint research initiatives
• Creates opportunities for shared grant funding
• Strengthens regulatory compliance through CLIA collaboration
• Enhances credibility within medical networks
• Facilitates integration into standard diagnostic workflows